Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Walmart, Inc
WARNING LETTER
•Walmart, Inc•August 18, 2023

Walmart, Inc – FDA Warning Letter, Aug 18, 2023

Record Details

The FDA issued a Warning Letter to Walmart concerning the distribution of "Naturasil Molluscum Treatment Kit" on www.walmart.com. The FDA purchased the product, which Walmart introduced into interstate commerce via Walmart Fulfillment Services.

The product is deemed an unapproved new drug under sections 505(a) and 201(p) of the FD&C Act because it is intended to treat molluscum contagiosum, a condition not amenable to self-diagnosis or treatment, and for which no legally marketed OTC drugs exist. Claims on the product's labeling, such as "Molluscum Treatment Kit" and "Symptomatic treatment of molluscum contagiosum," establish its intended drug use. The product is not generally recognized as safe and effective for its stated uses and lacks FDA approval.

The FDA expressed public health concerns, especially given the product's marketing for use in children, and the risk of individuals delaying proper diagnosis and treatment of potentially serious conditions. Even if considered homeopathic, the product contains non-homeopathic ingredients promoted with drug claims and would still fall under categories prioritized for enforcement due to potential higher public health risks.

Walmart is required to respond within fifteen working days, detailing steps taken to address violations, prevent recurrence, and ensure no further introduction of unapproved new drugs for molluscum contagiosum. Failure to comply may result in legal action, including seizure and injunction.

Company
Walmart, Inc
Inspection date
August 18, 2023
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Jill P. Furman (Director)
View Company Profile

ID · cef01c2c-549b-49dd-aaa6-8006fcb0f7b9

Violation Codes5
21.U.S.C. 355(a)21 U.S.C. 331(d)21 U.S.C. 321(g)(1)21 U.S.C. 321(p)21 CFR 201.66(b)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Walmart, Inc
  • WARNING_LETTER - 2025-11-26November 26, 2025
  • WARNING_LETTER - 2024-07-30July 30, 2024

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Walmart, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.